Zydus Lifesciences bags FDA tentative approval for Enzalutamide Tablets for prostate cancer treatment
Zydus Lifesciences Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for its Enzalutamide Tablets, available in 40 mg and 80 mg strengths. This significant approval marks a pivotal moment for the company, expanding its portfolio of cancer treatments and positioning it for a more substantial presence in the global […]